E. Läwitz

1.6k citations

59 papers · 1.1k indexed · h-index 22

Impact in

Hepatology top 0.5%
- Hepatitis C virus research
- Liver Disease and Transplantation
Epidemiology top 5%
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment

Papers in ⓘ

Hepatology 43
- Hepatitis C virus research 41
- Liver Diseases and Immunity 5
Genetics 10
- Chronic Lymphocytic Leukemia Research 10

Co-authors: M. Rodríguez‐Torres (19 shared papers)F. Poordad (10 shared papers)Ira M. Jacobson (11 shared papers)Mark Sulkowski (7 shared papers)William T. Symonds (7 shared papers)K.V. Kowdley (8 shared papers)Barry Bernstein (7 shared papers)M. Michelle Berrey (5 shared papers)
Journals: Journal of Hepatology (59 papers)
Partner nations: United States Germany Canada

In The Last Decade

E. Läwitz

59 papers receiving 1.1k citations

Peers

Countries citing papers authored by E. Läwitz

Since Specialization

Citations

This map shows the geographic impact of E. Läwitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Läwitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Läwitz more than expected).

Fields of papers citing papers by E. Läwitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Läwitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Läwitz. The network helps show where E. Läwitz may publish in the future.

Co-authors

The 25 scholars most cited alongside E. Läwitz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with E. Läwitz Line = papers co-authored together E. Läwitz links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 59 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3 Journal of Hepatology ·Mark Sulkowski, David Gardiner, E. Läwitz, Federico Hinestrosa, Daniel Nelson, Paul J. Thuluvath, M. Rodríguez‐Torres, Anna S. Lok, Howard Schwartz, K. Rajender Reddy, Timothy Eley, Megan Wind‐Rotolo, Shu‐Pang Huang, Min Gao, Fiona McPhee, R. Hindes, B. Symonds, C Pasquinelli, Dennis M. Grasela	2012	70
2	4 HCV SPRINT-1 FINAL RESULTS: SVR 24 FROM A PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRON™ (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT- NAIVE SUBJECTS WITH GENOTYPE-1 CHRONIC HEPATITIS C Journal of Hepatology ·Paul Y. Kwo, E. Läwitz, Jonathan McCone, E. Schiff, John M. Vierling, D. Pound, Mitchell Davis, Joseph Galati, S. Gordon, Natarajan Ravendhran, Lorenzo Rossaro, Frank Anderson, Ira M. Jacobson, Raymond A. Rubin, Kenneth Koury, Cliff Brass, Eman N. Chaudhri, J. Albrecht	2009	66
3	1399 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333 +RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS Journal of Hepatology ·F. Poordad, E. Läwitz, K.V. Kowdley, Gregory T. Everson, B. Freilich, Daniel E. Cohen, Sara Siggelkow, M. Heckaman, Rajeev Menon, T Matias, Thomas Podsadecki, Barry Bernstein	2012	54
4	3 SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/− RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY Journal of Hepatology ·K.V. Kowdley, E. Läwitz, F. Poordad, Daniel E. Cohen, Daniel W. Nelson, Stefan Zeuzem, Gregory T. Everson, Paul Y. Kwo, Graham R. Foster, Mark Sulkowski, Wen-Rui Xie, Lis Kjær Larsen, Arun Khatri, Thomas Podsadecki, Barry Bernstein	2013	47
5	58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION Journal of Hepatology ·Hendrik W. Reesink, H.L.A. Janssen, Stefan Zeuzem, E. Läwitz, M. Rodríguez‐Torres, KK Patel, Andren Chen, Christopher Davis, Bernard D. King, Adeera Levin, Michael R. Hodges	2012	45
6	61 ONCE DAILY PSI-7977 PLUS PEGIFN/RBV IN A PHASE 2B TRIAL: RAPID VIROLOGIC SUPPRESSION IN TREATMENT-NAIVE PATIENTS WITH HCV GT2/GT3 Journal of Hepatology ·Jacob Lalezari, E. Läwitz, M. Rodríguez‐Torres, Aasim Sheikh, B. Freilich, David R. Nelson, Tarek Hassanein, Malte Mäder, E. Albanis, William T. Symonds, M. Michelle Berrey	2011	37
7	1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS Journal of Hepatology ·Mark Sulkowski, M. Rodríguez‐Torres, E. Läwitz, M. Shiffman, S. Pol, Robert Herring, John G. McHutchison, Phil Pang, D. Brainard, D. Wyles, F. Habersetzer	2012	37
8	1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA <LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY) Journal of Hepatology ·E. Läwitz, M. Rodríguez‐Torres, Jill Denning, M. Cornpropsr, D. Clemons, Laura F. McNair, M. Michelle Berrey, William T. Symonds	2011	37
9	13 A 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R, ABT-072, AND RIBAVIRIN WAS WELL TOLERATED AND ACHIEVED SUSTAINED VIROLOGIC RESPONSE IN 91% TREATMENT-NAIVE HCV IL28B-CC GENOTYPE-1-INFECTED SUBJECTS Journal of Hepatology ·E. Läwitz, F. Poordad, K.V. Kowdley, Donald M. Jensen, David E. Cohen, Sara Siggelkow, Kjell Wikström, Lois Larsen, Rajeev Menon, Thomas Podsadecki, Barry Bernstein	2012	35
10	2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS Journal of Hepatology ·E. Läwitz, M. Rodriquez-Torres, Vinod K. Rustgi, Tarek Hassanein, Mohamad H. Rahimy, C. Crowley, James L. Freddo, A. Muir, John G. McHutchison	2010	34
11	[6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS Journal of Hepatology ·Nezam H. Afdhal, Claire O’Brien, Eliot Godofsky, M. Rodríguez‐Torres, S. Chris Pappas, E. Läwitz, Paul J. Pockros, Mark Sulkowski, Ira M. Jacobson, G. Chao, Steven Knox, Keith Pietropaolo, Nathaniel Brown	2007	34
12	736 Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb trial Journal of Hepatology ·Doug Dieterich, E. Läwitz, Nguyen Van Thanh, Ziad Younes, J. Santoro, Norman Gitlin, D. McEniry, Richard Chasen, J S Goff, Steven Knox, K. Kleber, Bruce Belanger, N. Brown	2006	34
13	1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1 Journal of Hepatology ·Ira M. Jacobson, Paul J. Pockros, Jacob Lalezari, E. Läwitz, M. Rodríguez‐Torres, E DeJesus, Felix Haas, Claudia Martorell, R. Pruitt, Katelin Durham, Subasree Srinivasan, Maria do Rosário, S. Jagannatha, Jennifer Hammond	2009	32
14	995 INTERIM RESULTS FROM HCV SPRINT-1: RVR/EVR FROM PHASE 2 STUDY OF BOCEPREVIR PLUS PEGINTRONTM (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN TREATMENT-NAIVE SUBJECTS WITH GENOTYPE-1 CHC Journal of Hepatology ·Paul Y. Kwo, E. Läwitz, Jonathan McCone, E. Schiff, John M. Vierling, D. Pound, Mitchell Davis, Joseph Galati, S. Gordon, Natarajan Ravendhran, Lorenzo Rossaro, Frank Anderson, Ira M. Jacobson, Raymond A. Rubin, Pabak Mukhopadhyay, Eman N. Chaudhri, Lisa D. Pedicone, J. Albrecht	2008	31
15	991 FINAL RESULTS OF THE IDEAL (INDIVIDUALIZED DOSING EFFICACY VERSUS FLAT DOSING TO ASSESS OPTIMAL PEGYLATED INTERFERON THERAPY) PHASE IIIB STUDY Journal of Hepatology ·Mark Sulkowski, E. Läwitz, M. Shiffman, Andrew J. Muir, Greg Galler, Jonathan McCone, L Nyberg, W.M. Lee, R. Ghalib, E. Schiff, Joseph Galati, B. Bacon, Mat D. Davis, P. Mukhopadhyay, Stephanie Noviello, Lisa D. Pedicone, J. Albrecht, J. McHutchison	2008	29
16	1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS Journal of Hepatology ·E. Läwitz, M. Rodríguez‐Torres, Melanie Cornpropst, Jill Denning, D. Clemons, Lindsay McNair, Lin Fang, M. Michelle Berrey, William T. Symonds	2012	29
17	39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 results Journal of Hepatology ·Nezam H. Afdhal, Ciara O Brien, Eliot Godofsky, M. Rodríguez‐Torres, S. Chris Pappas, Paul J. Pockros, E. Läwitz, N. Bzowej, Vinod K. Rustgi, Mark Sulkowski, K.E. Sherman, Ira M. Jacobson, G. Chao, Steven Knox, Keith Pietropaolo, N. Brown	2006	27
18	31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS Journal of Hepatology ·M. Rodríguez‐Torres, E. Läwitz, Barbara R. Conway, K. Kaita, Aasim Sheikh, R. Ghalib, Raúl Adrover, Curtis Cooper, Melissa Lou Silva, Maria do Rosário, B. Bourgault, L. Proulx, John G. McHutchison	2010	26
19	[14] CLEARANCE OF HCVRNA WITH VALOPICITABINE (NM) PLUS PEG-INTERFERON IN TREATMENT-NAIVE PATIENTS WITH HCV-1 INFECTION: RESULTS AT 24 AND 48 WEEKS Journal of Hepatology ·E. Läwitz, Nguyen Van Thanh, Ziad Younes, J. Santoro, Norman Gitlin, D. McEniry, Richard Chasen, J S Goff, Doug Dieterich, Steven Knox, K. Kleber, Bruce Belanger, N. Brown	2007	26
20	92 SAFETY, TOLERABILITY AND ANTIVIRAL ACTIVITY OF VCH-916, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR IN PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION Journal of Hepatology ·E. Läwitz, Curtis Cooper, M. Rodríguez‐Torres, R. Ghalib, RG Lalonde, Aasim Sheikh, B. Bourgault, Nathalie Chauret, L. Proulx, J. McHutchison	2009	22

About E. Läwitz

E. Läwitz is a scholar working on Hepatology, Genetics, Epidemiology, Immunology and Rheumatology, having authored 59 papers that have together received 1.1k indexed citations. Recurring topics across this work include Hepatitis C virus research (41 papers), Hepatitis B Virus Studies (17 papers), Immunodeficiency and Autoimmune Disorders (16 papers), Liver Disease Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (10 papers), Systemic Lupus Erythematosus Research (7 papers), Liver Diseases and Immunity (5 papers) and Pneumocystis jirovecii pneumonia detection and treatment (4 papers). The work is most often cited by research in Hepatology (1.0k citations), Epidemiology (939 citations), Infectious Diseases (339 citations), Rheumatology (104 citations) and Virology (19 citations). E. Läwitz has collaborated with scholars based in United States, Germany and Canada. Frequent co-authors include M. Rodríguez‐Torres, F. Poordad, Ira M. Jacobson, Mark Sulkowski, William T. Symonds, K.V. Kowdley, Barry Bernstein, M. Michelle Berrey, Thomas Podsadecki and John G. McHutchison. Their work appears in journals such as Journal of Hepatology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact